Trade

with

Charles River Laboratories International Inc
(NYSE: CRL)
AdChoices
61.83
-0.40
-0.64%
After Hours :
61.83
0.00
0.00%

Open

62.71

Previous Close

62.23

Volume (Avg)

267.52k (430.08k)

Day's Range

61.71-62.82

52Wk Range

47.33-62.82

Market Cap.

2.89B

Dividend Rate ( Yield )

-

Beta

0.95

Shares Outstanding

46.68M

P/E Ratio (EPS)

25.06 (2.44)

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Diagnostics & Research
Highlights
Analyst Recommendation: Hold
    • Revenue

    • 1.17B

    • Net Income

    • 102.83M

    • Market Cap.

    • 2.89B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • 9.61

    • PEG (Price/Earnings Growth) Ratio

    • 1.37

    • Beta

    • 0.95

    • Forward P/E

    • 17.18

    • Price/Sales

    • 2.43

    • Price/Book Value

    • 4.30

    • Price/Cash flow

    • 13.81

      • EBITDA

      • 255.93M

      • Return on Capital %

      • 6.74

      • Return on Equity %

      • 17.64

      • Return on Assets %

      • 6.74

      • Book Value/Share

      • 14.39

      • Shares Outstanding

      • 46.68M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Hold
        • 1 Year Price Target

        • 62.33

        • Credit Rating

        • BBB-

        • Analysts

        • 5

        • EPS Estimate

        • 3.39

        • Cashflow Estimate

        • 5.67

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 16.50

          • 21.91

          • Net Income

            YTD/YTD (last year)

          • 2.50

          • -5.55

          • Net Income

            Q/Q (last year)

          • 27.30

          • 0.44

          • Sales (Revenue)

            5-Year Annual Average

          • -2.80

          • 47.82

          • Net Income

            5-Year Annual Average

          • -

          • 4.98

          • Dividends

            5-Year Annual Average

          • -

          • 5.31

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 34.93

            • 42.70

            • Pre-Tax Margin

            • 13.04

            • 11.63

            • Net Profit Margin

            • 9.61

            • 9.55

            • Average Gross Margin

              5-Year Annual Average

            • 34.80

            • 43.76

            • Average Pre-Tax Margin

              5-Year Annual Average

            • 3.60

            • 11.34

            • Average Net Profit Margin

              5-Year Annual Average

            • 1.40

            • 52.13B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 1.16

              • 0.62

              • Current Ratio

              • 2.18

              • 1.23

              • Quick Ratio

              • 1.48

              • 0.76

              • Interest Coverage

              • 15.08

              • 5.98

              • Leverage Ratio

              • 2.77

              • 2.16

              • Book Value/Share

              • 14.39

              • 14.94

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • 25.06

                • 33.44

                • P/E Ratio 5-Year High

                • 25.49

                • 325.07

                • P/E Ratio 5-Year Low

                • 10.36

                • 154.73

                • Price/Sales Ratio

                • 2.43

                • 2.32

                • Price/Book Value

                • 4.30

                • 3.05

                • Price/Cash Flow Ratio

                • 13.81

                • 19.05

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • 17.64

                    (5.60)

                  • 9.34

                    (9.80)

                  • Return on Assets %

                    (5-Year Average)

                  • 6.74

                    (1.50)

                  • 4.63

                    (5.44)

                  • Return on Capital %

                    (5-Year Average)

                  • 9.06

                    (0.10)

                  • 5.73

                    (6.77)

                  • Income/Employee

                  • 15.25k

                  • 17.17k

                  • Inventory Turnover

                  • 8.78

                  • 5.07

                  • Asset Turnover

                  • 0.70

                  • 0.48

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  151.40M
                  Operating Margin
                  12.99
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  13.81
                  Ownership

                  Institutional Ownership

                  -

                  Top 10 Institutions

                  42.49%

                  Mutual Fund Ownership

                  59.96%

                  Float

                  98.20%

                  5% / Insider Ownership

                  3.86%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • ASTON/Fairpointe Mid Cap Fund

                  •  

                    1,278,219

                  • 3.17

                  • 2.74

                  • Ariel Fund

                  •  

                    1,036,626

                  • 6.00

                  • 2.22

                  • Invesco Select Companies Fund

                  •  

                    1,028,775

                  • 0.00

                  • 2.16

                  • First Trust NYSE Arca Biotech Fund

                  •  

                    838,624

                  • 1.77

                  • 1.87

                  • Vanguard Small Cap Index

                  •  

                    810,832

                  • -3.83

                  • 1.74

                  • Vanguard Explorer Fund

                  •  

                    804,620

                  • 1,390.04

                  • 1.72

                  • Vanguard Strategic Equity Fund

                  •  

                    801,300

                  • 4.12

                  • 1.72

                  • Vanguard Total Stock Mkt Idx

                  •  

                    785,683

                  • 0.48

                  • 1.68

                  • BlackRock Health Sciences Opps Port

                  •  

                    675,900

                  • 4.43

                  • 1.45

                  • Vanguard Capital Opportunity Fund

                  •  

                    660,000

                  • 0.00

                  • 1.41

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Vanguard Group, Inc.

                  •  

                    3,889,296

                  • +9.07%

                  • 8.29

                  • Wellington Management Company, LLP

                  •  

                    3,433,518

                  • +33.51%

                  • 7.32

                  • Ariel Investments, LLC

                  •  

                    1,950,657

                  • -2.92%

                  • 4.16

                  • Acadian Asset Management LLC

                  •  

                    1,869,520

                  • +342.74%

                  • 3.99

                  • PRIMECAP Management Company

                  •  

                    1,696,800

                  • -0.06%

                  • 3.62

                  • Fairpointe Capital LLC

                  •  

                    1,680,694

                  • +7.90%

                  • 3.58

                  • Fidelity Management and Research Company

                  •  

                    1,531,690

                  • +1.61%

                  • 3.27

                  • BlackRock Fund Advisors

                  •  

                    1,389,340

                  • -4.81%

                  • 2.96

                  • State Street Corp

                  •  

                    1,245,270

                  • +0.46%

                  • 2.66

                  • BlackRock Advisors LLC

                  •  

                    1,237,987

                  • -0.46%

                  • 2.64

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Diagnostics & Research

                  Type

                  Slow Growth

                  Style

                  Small Core

                  Charles River Laboratories International Inc was incorporated in 1994 in Delaware and in 2000 it completed its initial public offering. Its portfolio includes research models and services required to enablein vivo drug discovery and ...moredevelopment. Discovery represents the earliest stages of research in the life sciences, directed at the identification, screening and selection of a lead compound for future drug development. Discovery activities typically extend anywhere from 4-6 years in conventional pharmaceutical research and development timelines. Development activities, which follow, and which can take up to 7-10 years, are directed at demonstrating the safety, tolerability and clinical efficacy of the selected drug candidates. During the preclinical stage of the development process, a drug candida...morete is tested in vitro (typically on a cellular or sub-cellular level in a test tube or multi-well petri plate) and in vivo (in research models) to support planned or on-going human trials. The Company operates in two segments, namely Research Models and Services (RMS) and Preclinical Services (PCS). Through its RMS segment, the Company supplies research models to the drug development industry. It also provides a variety of related services that are designed to assist its clients in supporting the use of research models in drug discovery and development. With multiple facilities located on three continents (North America, Europe and Asia), it maintains production centers, including barrier rooms and/or isolator facilities. Its PCS business segment provides services that enable its clients to outsource their critical, regulatory-required safety assessment and related drug development activities to the Company. Its RMS segment is comprised of Research Models, Research Model Services and Endotoxin and Microbial Detection. Its Research Models business is comprised of the production and sale of research models and avian vaccine services. Research Model Services also offers a variety of services designed to support its clients' use of research models in screening drug candidates. Its Endotoxin and Microbial Detection business provides non-animal, or in vitro, methods for lot release testing of medical devices and injectable drugs for endotoxin contamination. The Company currently offers preclinical services, both regulated and non-regulated, in which it includes both in vivo and in vitro studies, supporting laboratory services, and strategic preclinical consulting and program management to support product development. The Company’s customers include global biopharmaceutical companies, small and mid-sized pharmaceutical companies and biotechnology companies, and academic and government institutions. The Company competes in the marketplace on the basis of therapeutic and scientific expertise in in vivo biology, quality, reputation, flexibility, responsiveness, pricing, innovation and global capabilities. The Company’s business operates in a number of distinct operating environments and in a variety of locations worldwide are subject to numerous, and sometimes overlapping, regulatory environments.lessless

                  Key People

                  James C. Foster

                  CEO/Chairman of the Board/President/Director

                  Thomas F. Ackerman

                  CFO/Executive VP

                  Nancy Gillett,PhD

                  Chief Scientific Officer/Executive VP

                  Jorg M. Geller

                  Executive VP, Divisional

                  Dr. Davide Molho,D.V.M.

                  Executive VP/President, Divisional

                  • Charles River Laboratories International Inc

                  • 251 Ballardvale Street

                  • Wilmington, MA 01887

                  • USA.Map

                  • Phone: +1 781 222-6000

                  • Fax: +1 978 988-5665

                  • criver.com

                  Incorporated

                  1994

                  Employees

                  7,700

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: